<DOC>
	<DOCNO>NCT00324155</DOCNO>
	<brief_summary>The purpose clinical research study examine safety effectiveness ( well drug work ) two different treatment patient melanoma . One treatment investigational compound ( drug currently approve United States Food Drug Administration [ FDA ] ) , know Ipilimumab ( also know MDX-010 BMS-734016 ) together approve chemotherapy drug call Dacarbazine</brief_summary>
	<brief_title>Dacarbazine Ipilimumab vs. Dacarbazine With Placebo Untreated Unresectable Stage III IV Melanoma</brief_title>
	<detailed_description>For extension phase : Allocation : single arm study ; Masking : open label ; Intervention Model : Single Group</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Informed Consent Measurable Disease Eastern Cooperative Oncology Group ( ECOG ) 0 1 Lab / imaging requirement Neg Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( HepB ) , C Men Women &gt; 18 year ( 16 allowable ) Prior therapy restriction ( adjuvant ) Exclusion : Pregnant / nursing Inadequate contraception Brain metastasis Primary ocular mucosal melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Stage IIIc N3 ( unresectable )</keyword>
	<keyword>Stage IV melanoma</keyword>
</DOC>